Paolo Tarantino: Frontline treatment strategy for metastatic HER2+ breast cancer
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, posted on LinkedIn:
“Over the past decade, we’ve been using the same first-line treatment strategy for HER2+ metastatic breast cancer: CLEOPATRA
Induction taxane/HP followed by dual HER2 blockade maintenance.
We did however fine-tune this regimen:
– PERUSE unlocked the use of a better tolerated paclitaxel induction backbone
– EMERALD offered an alternative eribulin backbone
– PATINA introduced the concept of CDK4/6i (palbociclib) maintenance. We’re now on the verge of a paradigm switch: with DB09 expected to report soon, the HER2 ADC trastuzumab deruxtecan (T-DXd) may replace CLEOPATRA, at least for some patients.
The hope: to cure more patients from their metastatic HER2+ disease.
The challenge: ensuring a good quality of life for patients that face years of systemic treatment.
And preventing/mitigating ILD, which remains a life-threatening risk with T-DXd.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023